Fedratinib (FEDR) in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) previously treated with Ruxolitinib (RUX): a reanalysis of the phase 2 Jakarta-2 study

A. Reiter, C. N. Harrison, K. Doehner, F. Heidel, H. Gisslinger, D. Niederwieser,N. Schaap, A. M. Vannucchi,J. -J. Kiladjian, E. Jourdan, R. T. Silver,H. C. Schouten, F. Passamonti,S. Zweegman, M. Talpaz,S. Verstovsek, T. Gerike,S. Rose,M. Li, C. Brownstein, R. A. Mesa

ONCOLOGY RESEARCH AND TREATMENT（2019）

Cited 0|Views6

No score

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined